ABL1 F317I Recombinant Human Active Protein Kinase

The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 F317I Recombinant Human Active Protein Kinase is a recombinant ABL1 F317I protein that can be used to study ABL1 F317I-related functions[1].